ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated
dose of ABT-348 as monotherapy and when given in combination with carboplatin or docetaxel.